YAP1 and non-small cell lung carcinoma: To explore the potential synergistic effects, it is necessary to investigate the efficacy of the combination of YAP inhibition and anti-PD-L1/PD-1 immune checkpoint inhibitors (ICIs) for NSCLC patients resistant to EGFR-TKIs.